GC Wealth Management RIA’s NovoCure NVCR Stock Holding History

GC Wealth Management RIA’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-23,016	Closed	-$297K	–	745
2025 Q3	$297K	Buy	+23,016	New	+$308K	0.01%	710

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

GC Wealth Management RIA's NVCR Position: Q4 2025 in Review

GC Wealth Management RIA sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 23,016 shares — an estimated $297K sold.

GC Wealth Management RIA first reported a position in NVCR in Q3 2025 and held it in 1 quarter. The position peaked at $297K in Q3 2025. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

GC Wealth Management RIA reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
GC Wealth Management RIA sold 23,016 NovoCure shares in Q4 2025, an estimated $297K.
GC Wealth Management RIA first reported a position in NovoCure in Q3 2025 and held it in 1 quarter.
GC Wealth Management RIA's NovoCure position peaked at $297K in Q3 2025.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on GC Wealth Management RIA's 13F filing for Q4 2025, filed 30 Jan 2026.